Antimutagenicity of amifostine against the anticancer drug fotemustine in the Drosophila somatic mutation and recombination (SMART) test

Autor: N. Sevim, Ozgur Vatan, Rahmi Bilaloglu, Nilüfer Aydemir, Serap Celikler
Přispěvatelé: Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü., Çinkılıç, Nilüfer, Sevim, Neşe, Çelikler, Serap, Vatan, Özgür, Bilaloğlu, Rahmi, AAH-2767-2021, AAH-5296-2021, O-7508-2015
Rok vydání: 2009
Předmět:
Health
Toxicology and Mutagenesis
medicine.medical_treatment
Wr-2721
Normal tissue
Mutagenicity tests
Pharmacology
Toxicology
Agent
Amifostine
2 (3 Aminopropylamino)Ethanethiol
Radioprotective Effect
Mutagenicity
Antineoplastic agents
Fotemustine
Bleomycin-genotoxicity
Cancer
Priority journal
Genetics
Heterozygosity
Biotechnology & applied microbiology
Genetics & heredity
Antimutagenic agents
Anticancer drug
Cytoprotective Agent
Drosophila melanogaster
Larva
Antimutagenicity
Melanoma cell-lines
Female
Wing spot-test
medicine.drug
Organophosphorus compounds
Genotype
Drosophila SMART assay
Recombination
genetic
Biology
Article
Germline mutation
Melanogaster
medicine
Animals
Gene mutation
Cyclophosphamide
Genetic marker
Chemotherapy
Radiotherapy
Toxicity
Genetic recombination
fungi
Molecular cloning
Nonhuman
medicine.disease
Nitrosourea compounds
Controlled study
Zdroj: Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 679:1-5
ISSN: 1383-5718
Popis: Amifostine (WR-2721), a phosphorylated aminothiol pro-drug, is a selective cytoprotective agent in normal tissue against the toxicities associated with chemotherapy and irradiation. Fotemustine is a cancer chemotherapeutic agent that belongs to an extremely active class of alkylating compounds. Amifostine was tested for antimutagenicity against fotemustine in the somatic mutation and recombination test (SMART) in Drosophila melanogaster . Third-instar larvae that were trans -heterozygous for the two genetic markers mwh and flr were treated at different concentrations (2, 4, and 8 μg/ml for fotemustine and, 1, 2, and 4 μg/ml for amifostine) of the test compounds; for the antimutagenicity study, 8 μg/ml fotemustine plus 1 and 2 μg/ml amifostine were tested. Fotemustine showed mutagenic and recombinagenic effects in both genotypes in the wing-spot test. Amifostine significantly reduced the mutagenic and recombinagenic effects of fotemustine.
Databáze: OpenAIRE
Externí odkaz: